BCL2 and leukemia: To demonstrate whether the reduced survival in the HMC-1.3 cell line may be consequential under stress conditions, we treated the cells with an inhibitor of BCL2, a treatment approved for leukemia that has been shown to promote apoptosis in HMC-1 cells and proposed as a potential therapy for advanced mastocytosis (42).